Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer

Hiroshi Sawayama, Takatsugu Ishimoto, Masayuki Watanabe, Naoya Yoshida, Hidetaka Sugihara, Junji Kurashige, Kotaro Hirashima, Masaaki Iwatsuki, Yoshifumi Baba, Eiji Oki, Masaru Morita, Yoshinobu Shiose, Hideo Baba

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The transcription factor PPAR-γ plays various roles in lipid metabolism, inflammation, cellular differentiation, and apoptosis. PPAR-γ agonists used to treat diabetes may have utility in cancer treatment. Efatutazone is a novel later generation PPAR-γ agonist that selectively activates PPAR-γ target genes and has antiproliferative effects in a range of malignancies. In this study, we investigated PPAR-γ status in esophageal squamous cell carcinoma (ESCC) and investigated the antiproliferative effects of efatutazone. PPAR-γ was expressed heterogeneously in ESCC, in which it exhibited an inverse relationship with Ki-67 expression. PPAR-γ expression was associated independently with good prognosis in ESCC. Efatutazone, but not the conventional PPAR-γ agonist troglitazone, inhibited ESCC cell proliferation in vitro and in vivo. Mechanistic investigations suggested that efatutazone acted by upregulating p21Cip1 protein in the nucleus through inactivation of the Akt pathway and dephosphorylation of p21Cip1 at Thr145 without affecting the transcriptional activity of p21Cip1. We also found that treatment with efatutazone led to phosphorylation of the EGF receptor and activation of the mitogen-activated protein kinase (MAPK) pathway. Accordingly, the combination of efatutazone with the antiepithelial growth factor receptor antibody cetuximab synergized to negatively regulate the phosphoinositide 3-kinase-Akt and MAPK pathways. Together, our results suggest that efatutazone, alone or in combination with cetuximab, may offer therapeutic effects in ESCC.

Original languageEnglish
Pages (from-to)575-585
Number of pages11
JournalCancer Research
Volume74
Issue number2
DOIs
Publication statusPublished - Jan 15 2014

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Sawayama, H., Ishimoto, T., Watanabe, M., Yoshida, N., Sugihara, H., Kurashige, J., ... Baba, H. (2014). Small molecule agonists of PPAR-γ exert therapeutic effects in esophageal cancer. Cancer Research, 74(2), 575-585. https://doi.org/10.1158/0008-5472.CAN-13-1836